MedTrace Logo

Recombinant Human Relaxin for the Treatment of Decompensated CHF

NCT00406575 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2014-05-07

No results posted yet for this study

Summary

Two doses of relaxin will be compared to placebo for the treatment of patients with decompensated CHF

Conditions

  • Congestive Heart Failure (CHF)

Interventions

DRUG

Placebo

Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.

DRUG

Recombinant human relaxin (rhRlx)

Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.

Sponsors & Collaborators

  • Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

    lead INDUSTRY

Principal Investigators

  • Thomas Dschietzig, MD · Charite Hospital, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406575 on ClinicalTrials.gov